Unidad de Atencion Medica e Investigacion en Salud (UNAMIS) | Clinical Protocols Department

Research site

Location

Calle 33-A No. 505 entre 72 y 72-A Colonia Centro, Merida, Yucatán, Mexico

Site insights

Top conditions

Top treatments

Risankizumab

Ontamalimab

HZN-825

Celecoxib

Doravirine

Afimetoran

Avastin

CC-220

Pregabalin

PF04965842

Data sourced from clinicaltrials.gov

Contact this site

Juan José Rivera Alcocer

Verified by this site

Active trials

6 of 21 total trials

A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial. Participants will be screened within 6 weeks prior to the Bas...

Enrolling

Diffuse Cutaneous Systemic Sclerosis

Sclerosis, Systemic

Drug: Placebo

Drug: HZN-825 QD

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythema...

Enrolling

Systemic Lupus Erythematosus

Other: Placebo

Drug: Afimetoran

A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease (FORTIFY)

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting

Crohn's Disease

Drug: Placebo for Risankizumab IV

Drug: Risankizumab SC

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who respond...

Active, not recruiting

Ulcerative Colitis (UC)

Drug: placebo for risankizumab

Drug: risankizumab

Locations recently updated

An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)

Primary Objectives:1. The primary efficacy objective is to assess the efficacy of 52 weeks of open-label treatment with HZN-825 in participants with...

Invitation-only

Diffuse Cutaneous Systemic Sclerosis

Sclerosis, Systemic

Drug: HZN-825

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Ages 4 Weeks to <12 Years and <45 kg (MK-1439-066)

This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 wee...

Enrolling

Human Immunodeficiency Virus (HIV) Infection

Drug: 2 NRTIs

Drug: Doravirine